[1] S. Shiina, R. Tateishi, T. Arano, et al., “Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors,” American Journal of Gastroenterology, Vol. 107, No. 4, 2012, pp. 569-577. doi:10.1038/ajg.2011.425
[2] H. Imamura, Y. Matsuyama, E. Tanaka, et al., “Risk Factors Contributing to Early and Late Phase Intrahepatic Recurrence of Hepatocellular Carcinoma after Hepatectomy,” Journal of Hepatology, Vol. 38, No. 2, 2003, pp. 200-207. doi:10.1016/S0168-8278(02)00360-4
[3] M. Kudo, et al., “Report of the 18th Nationwide Follow-Up Survey of Primary Liver Cancer in Japan,” Kanzo (in Japanese), Vol. 51, No. 8, 2010, pp. 460-484.
[4] T. Ishikawa, K. Higuchi, T. Kubota, et al., “Combination PEG-IFN-2b/Ribavirin Therapy Following Treatment of Hepatitis C Virus-Associated Hepatocellular Carcinoma Is Capable of Improving Hepatic Functional Reserve and Survival,” Hepatogastroenterology, Vol. 59, No. 114, 2012, pp. 529-532. doi:10.5754/hge10867
[5] N. Kokudo and M. Makuuchi, “Evidence-Based Clinical Practice Guidelines for Hepatocellular Carcinoma in Japan: The J-HCC Guidelines,” Journal of Gastroenterology, Vol. 44, No. 19, 2009, pp. 119-121. doi:10.1007/s00535-008-2244-z
[6] M. Kudo, N. Izumi, N. Kokudo, HCC Expert Panel of Japan Society of Hepatology, et al., “Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version,” Digestive Diseases, Vol. 29, No. 3, 2011, pp. 339-364. doi:10.1159/000327577
[7] S. Togo, K. Tanaka, H. Masui, et al., “Usefulness of Prophylactic Transcatheter Arterial Infusion of Anticancer Agents with Lipiodol to Prevent Recurrence of Hepatocellular Carcinoma after Hepatic Resection,” International Surgery, Vol. 90, No. 2, 2005, pp. 103-108.
[8] M. Satake, H. Uchida, Y. Arai, et al., Transcatheter Arterial Chemoembolization (TACE) with Lipiodol to Treat Hepatocellular Carcinoma: Survey Results from the TACE Study Group of Japan,” CardioVascular and Interventional Radiology, Vol. 31, No. 4, 2008, pp. 756-761. doi:10.1007/s00270-007-9255-7
[9] K. Takayasu, S. Arii, I. Ikai, Liver Cancer Study Group of Japan, et al., “Overall Survival after Transarterial Lipiodol Infusion Chemotherapy with or without Embolization for Unresectable Hepatocellular Carcinoma: Propensity Score Analysis,” American Journal of Roentgenology, Vol. 194, No. 3, 2010, pp. 830-837. doi:10.2214/AJR.09.3308
[10] H. Yodono, K. Matsuo and A. Shinohara, “A Retrospective Comparative Study of Epirubicin-Lipiodol Emulsion and Cisplatin-Lipiodol Suspension for Use with Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma,” Anticancer Drugs, Vol. 22, No. 3, 2011, pp. 277-282. doi:10.1097/CAD.0b013e328342231d
[11] K. Kasai, A. Ushio, K. Sawara, et al., “Transcatheter Arterial Chemoembolization with a Fine-Powder Formulation of Cisplatin for Hepatocellular Carcinoma,” World Journal of Gastroenterology, Vol. 16, No. 27, 2010, pp. 3437-3444. doi:10.3748/wjg.v16.i27.3437
[12] ACE500 Study. https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows &type=summary&recptno=R000001678&language=E
[13] M. Ikeda, Y. Arai, et al., “Transcatheter Arterial Chemoembolization with Epirubicin and Lipiodol for Unresectable Hepatocellular Carcinoma-Subgroup Analysis of Japanese Patients in Cooperative Study between Korea and Japan,” Japanese Journal of Radiology, Vol. 27, 2012, pp. 299-304.
[14] K. Yamakado, S. Miyayama, S. Hirota, et al., “Hepatic Arterial Embolization for Unresectable Hepatocellular Carcinomas: Do Technical Factors Affect Prognosis?” Japanese Journal of Interventional Radiology, Vol. 30, No. 7, 2012, pp. 560-566. doi:10.1007/s11604-012-0088-1
[15] K. Osuga, Y. Arai, H. Anai, et al., “Phase I/II Multicenter Study of Transarterial Chemoembolization with a Cisplatin Fine Powder and Porous Gelatin Particles for Unresectable Hepatocellular Carcinoma: Japan Interventional Radiology in Oncology Study Group Study 0401,” Journal of Vascular and Interventional Radiology, Vol. 23, No. 10, 2012, pp. 1278-1285. doi:10.1016/j.jvir.2012.06.028
[16] T. Ishikawa, K. Higuchi, T. Kubota, et al., “Prevention of Intrahepatic Distant Recurrence by Transcatheter Arterial Infusion Chemotherapy with Platinum Agents for Stage I/II Hepatocellular Carcinoma,” Cancer, Vol. 117, No. 17, 2011, pp. 4018-4025. doi:10.1002/cncr.25989
[17] J. Bruix and M. Sherman, “American Association for the Study of Liver Diseases. Management of Hepatocellular Carcinoma: An Update,” Hepatology, Vol. 53, No. 3, 2011, pp. 1020-1022. doi:10.1002/hep.24199
[18] T. Ishikawa, M. Imai, H. Kamimura, et al., “Improved Survival for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Treated by Intra-Arterial Chemotherapy Combining Etoposide, Carboplatin, Epirubicin and Pharmacokinetic Modulating Chemotherapy by 5-FU and Enteric-Coated Tegafur/Uracil: A Pilot Study,” World Journal of Gastroenterology, Vol. 13, No. 41, 2007, pp. 5465-5470.
[19] T. Ishikawa, “Future Perspectives on the Treatment of Hepatocellular Carcinoma with Cisplatin,” World Journal of Hepatology, Vol. 1, No. 1, 2009, pp. 8-16. doi:10.4254/wjh.v1.i1.8